Photo from wikipedia
Heparin management in hemophilia A (HA) patients with a factor VIII (FVIII) inhibitor can be challenging due to severe activated clotting time (ACT) prolongations. It is important to better understand… Click to show full abstract
Heparin management in hemophilia A (HA) patients with a factor VIII (FVIII) inhibitor can be challenging due to severe activated clotting time (ACT) prolongations. It is important to better understand the impact of emicizumab, a FVIII mimetic on ACT, and tissue factor (TF)‐based coagulation assays.
Keywords:
emicizumab activated;
vitro effects;
activated clotting;
clotting time;
effects emicizumab
Journal Title: Haemophilia
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!